CoreRx, an industry CDMO, completed the acquisition of Societal CDMO, an organisation providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, packaging, and logistics services to the global pharmaceutical market, for $130m. “The enhanced CDMO that will be created through this transaction will be positioned to offer both existing and new customers strength in formulation development, early-stage production, clinical trial services, commercial-scale manufacturing, and a range of packaging services. The prospects for this combined entity to establish itself as a preferred CDMO partner in the small molecule space are bright and we look forward to the opportunity to contribute to the new company’s success. We are proud to see our team’s accomplishments and are truly grateful for the contributions made by all team members to the success of the company. I am confident that this transaction will maximize value for our shareholders,” David Enloe, Societal CDMO CEO.